Pharmaceutical News and Articles
Clinical Trial Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix,
Inc., a biopharmaceutical company advancing orally-available
antiviral therapeutics to address life-threatening diseases,
presented updates on the development of the company's...
SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration
with scientists at the Centers for Disease Control and Prevention
(CDC), St. Louis University, and the University of Hong Kong,
announced today the publication of two articles in...
ITCA 650 induces potent reductions of HbA1c and body weight
after 4 week treatment; ITCA 650 delivers up to 12 months of
exenatide therapy from a single DUROS device
HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics,
Inc. delivered two...
Oncolytics Biotech® Inc. Collaborators Present Positive
Phase II Sarcoma Trial Results at CTOS Annual Meeting
CALGARY, AB, November 6, 2009 - Oncolytics Biotech Inc.
(TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the
“Company”)...
-- Palifosfamide prolongs progression-free survival by at
least 50% --
NEW YORK--(BUSINESS WIRE)--Nov 6, 2009 - ZIOPHARM Oncology, Inc.
(Nasdaq: ZIOP) presented today at the 15th Annual
Connective Tissue Oncology Society (CTOS) Meeting, positive...
ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant
Pharmaceuticals (NYSE: VRX) today announced that results from the
week-72 analysis for its Phase IIb dose-finding clinical trial for
taribavirin, a prodrug of ribavirin which is in...
Cambridge (United Kingdom), 5 November 2009: New data published
today in the journal, Cancer, reveals that three quarters (75%) of
patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL),
responded to treatment with Bendamustine following a...
Frazer, Pa. – November 5, 2009 – Cephalon, Inc.
(Nasdaq: CEPH) today announced the journal Cancer has published a
pivotal study demonstrating that TREANDA® (bendamustine HCl)
for Injection induced durable responses in patients with...
Sanofi Pasteur Presents Safety Data on Menactra® Vaccine
Given to Infants at Infectious Disease Society Meeting
The two-dose meningococcal quadrivalent conjugate vaccine was
generally well-tolerated
Philadelphia, PA – November 2, 2009...
Large study finds subset of women that may need additional
therapy
HOUSTON , Nov. 2, 2009- Early-stage breast cancer patients with
HER2 positive tumors one centimeter or smaller are at significant
risk of recurrence of their disease, compared...
ROCHESTER, N.Y., Nov. 5 /PRNewswire-USNewswire/ -- A drug
already approved for the treatment of lymphoma may also slow the
growth of the most deadly bone cancer in children and teens,
according to an early-stage study published online today in...
Phase 3 Results Reinforce Importance of KRAS Status
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen
(NASDAQ:
AMGN) today announced that the Phase 3 PRIME "203" trial
evaluating Vectibix® (panitumumab) administered in...
AST-120 Also Shown to Reduce Ammonia and Brain Swelling in
Rat Model of Cirrhosis
BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc.
announced today that AST-120 (spherical carbon adsorbent) was shown
to reduce the severity of pruritus...
Complete durable eradication of disease achieved in a
significant number of patients with investigational therapy for
advanced Stage III and Stage IV melanoma
WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company
developing new generation...
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Short-term hormone
therapy given prior to and during radiation treatment to
medium-risk prostate cancer patients increases their chance of
living longer, compared to those who receive radiation...
The Autism Research Institute calls for further
investigations into the use of chelation therapy for individuals
with autism
SAN DIEGO, Nov. 5 /PRNewswire-USNewswire/ -- Two studies
published by the Southwest College of Naturopathic Medicine in...
Findings from Pfizer-Sponsored Study Presented as
Late-Breaker at American College of Chest Physicians Annual
Meeting
SAN DIEGO--(BUSINESS WIRE)--Nov 4, 2009 - New study results
showed that 42.3 percent of smokers with mild-to-moderate...
– Research Findings Include Rational Design of Mimetic
Lipoprotein Particles (MLPs), a Novel Delivery Technology, New Data
Regarding Potency of RNAi-Mediated Gene Silencing, and an Update on
RNA Activation Research Efforts –
CAMBRIDGE,...
LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today
show that CONCERTA® (OROS® methylphenidate HCl
Extended-Release Tablets CII) is the only stimulant medication with
data that demonstrate a significant treatment effect on...
LAS VEGAS, Nov. 4, 2009 – New findings presented today
show that CONCERTA® (OROS® methylphenidate HCl
Extended-Release Tablets CII) is the only stimulant medication with
data that demonstrate a significant treatment effect on attention
at...
More...
